No Data
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $87
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
Express News | Astrazeneca, Eli Lilly and Co, Asia Fund, and others invested in Chengyuan Technology.
GRAIL Announces The First Patient Has Been Tested For Eligibility With Its Non-Small Cell Lung Cancer CtDNA Assay In The TROPION-Lung12 Phase 3 Study, Sponsored By AstraZeneca In Collaboration With Daiichi Sankyo
AstraZeneca Picks First Treg Cell Therapy From Quell Therapeutics Partnership
Astrazeneca (AZN) Is a Top-Ranked Growth Stock: Should You Buy?